Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 228

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Efficacy of Sertraline in Preventing Relapse of Posttraumatic Stress Disorder: Results of a 28-Week Double-Blind, Placebo-Controlled Study

Davidson, Jonathan, Pearlstein, Teri, Londborg, Peter, Brady, Kathleen T., Rothbaum, Barbara, Bell, Jon, Maddock, Richard, Hegel, Mark T., Farfel, Gail·2001·American Journal of Psychiatry

Abstract

OBJECTIVE: The study examined the efficacy of sertraline, compared with placebo, in sustaining improvement and preventing relapse over 28 weeks in patients with posttraumatic stress disorder (PTSD) who had completed a 12-week double-blind, placebo-controlled acute treatment study and a subsequent 24-week open-label study of continuation treatment with sertraline. METHOD: Ninety-six patients were randomly assigned, in a double-blind design, to 28 weeks of maintenance treatment with sertraline (50-200 mg, N=46; 78% were women) or placebo (N=50; 62% were women). Measures used in biweekly assessments included the Clinician-Administered PTSD Scale, the Impact of Event Scale, and the Clinical Global Impression severity and improvement ratings. Kaplan-Meier analyses were used to estimate time to discontinuation from the study due to relapse, relapse or study discontinuation due to clinical deterioration, and acute exacerbation. RESULTS: Continued treatment with sertraline yielded lower PTSD relapse rates than placebo (5% versus 26%). Patients who received placebo were 6.4 times as likely to experience relapse as were patients who received sertraline. Kaplan-Meier analyses confirmed the protective effect of sertraline in significantly extending time in remission. The ability of sertraline to sustain improvement was comparable across the three core PTSD symptom clusters (reexperiencing/intrusion, avoidance/numbing, and hyperarousal). A regression analysis found early response during acute treatment to be associated with a more than 16-fold reduced risk of relapse after placebo substitution. Sertraline, at a mean endpoint dose of 137 mg, was well tolerated, with no sertraline-related adverse events observed at a rate of 10% or higher. CONCLUSIONS: The results provide evidence for the ability of sertraline both to sustain improvement in PTSD symptoms and to provide prophylactic protection against relapse.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1176/appi.ajp.158.12.1974

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 35

  1. Breslau N, Davis GC: Posttraumatic stress disorder in an urban population of young adults: risk factors for chronicity. Am J Psychiatry 1992; 149:671-675 · DOI · Paper page
  2. Solomon SD, Davidson JR: Trauma: prevalence, impairment, service use, and cost. J Clin Psychiatry 1997; 58:5-11
  3. Kimerling R, Calhoun KS: Somatic symptoms, social support, and treatment-seeking among sexual assault victims. J Consult Clin Psychol 1994; 62:333-340 · DOI · Paper page
  4. Zatzick DF, Marmar CR, Weiss DS, Browner WS, Metzler TJ, Golding JM, Stewart A, Schlenger WE, Wells KB: Posttraumatic stress disorder and functioning and quality of life outcomes in a nationally representative sample of male Vietnam veterans. Am J Psychiatry 1997; 154:1690-1695 · DOI · Paper page
  5. Warshaw MG, Fierman E, Pratt L, Hunt M, Yonkers KA, Massion AO, Keller MB: Quality of life and dissociation in anxiety disorder patients with histories of trauma or PTSD. Am J Psychiatry 1993; 150:1512-1516 · DOI · Paper page
  6. Amaya-Jackson L, Davidson JR, Hughes DC, Swartz M, Reynolds V, George LK, Blazer DG: Functional impairment and utilization of services associated with posttraumatic stress in the community. J Trauma Stress 1999; 12:709-724 · DOI · Paper page
  7. Brom D, Kleber RJ, Defares PB: Brief psychotherapy for posttraumatic stress disorders. J Consult Clin Psychol 1989; 57:607-612 · doi:10.1037//0022-006x.57.5.607 · Paper page
  8. Marks I, Lovell K, Noshirvani H, Livanou M, Thrasher S: Treatment of posttraumatic stress disorder by exposure and/or cognitive restructuring: a controlled study. Arch Gen Psychiatry 1998; 55:317-325 · DOI · Paper page
  9. Cahill SP, Carrigan MH, Frueh BC: Does EMDR work? And if so, why? a critical review of controlled outcome and dismantling research. J Anxiety Disord 1999; 13:5-33 · DOI
  10. Shapiro F: Eye movement desensitization and reprocessing (EMDR): evaluation of controlled PTSD research. J Behav Ther Exp Psychiatry 1996; 27:209-218 · DOI · Paper page
  11. Boudewyns PA, Hyer L: Physiological response of combat memories and preliminary treatment outcome in Vietnam veteran PTSD patients treated with direct therapeutic exposure. Behav Ther 1990; 21:63-87 · DOI · Paper page
  12. Foa EB, Dancu CV, Hembree EA, Jaycox LH, Meadows EA, Street GP: A comparison of exposure therapy, stress inoculation training, and their combination for reducing posttraumatic stress disorder in female assault victims. J Consult Clin Psychol 1999; 67:194-200 · DOI · Paper page
  13. Kosten TR, Frank JB, Dan E, McDougle CJ, Giller EL Jr: Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis 1991; 179:366-370 · DOI · Paper page
  14. Davidson J, Kudler H, Smith R, Mahorney SL, Lipper S, Hammett E, Saunders WB, Cavenar JO Jr: Treatment of posttraumatic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry 1990; 47:259-266 · DOI · Paper page
  15. van der Kolk BA, Dreyfuss D, Michaels M, Shera D, Berkowitz R, Fisler R, Saxe G: Fluoxetine in posttraumatic stress disorder. J Clin Psychiatry 1994; 55:517-522
  16. Connor KM, Sutherland SM, Tupler LA, Malik ML, Davidson JR: Fluoxetine in post-traumatic stress disorder: randomised, double-blind study. Br J Psychiatry 1999; 175:17-22 · DOI · Paper page
  17. Brady KT, Sonne SC, Roberts JM: Sertraline treatment of comorbid posttraumatic stress disorder and alcohol dependence. J Clin Psychiatry 1995; 56:502-505
  18. Rothbaum BO, Ninan PT, Thomas L: Sertraline in the treatment of rape victims with posttraumatic stress disorder. J Trauma Stress 1996; 9:865-871 · DOI
  19. Marshall RD, Schneier FR, Fallon BA, Knight CB, Abbate LA, Goetz D, Campeas R, Liebowitz MR: An open trial of paroxetine in patients with noncombat-related, chronic posttraumatic stress disorder. J Clin Psychopharmacol 1998; 18:10-18 · DOI
  20. Brady K, Pearlstein T, Asnis GM, Baker D, Rothbaum B, Sikes CR, Farfel GM: Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA 2000; 283:1837-1844 · DOI · Paper page
  21. Davidson JR, Rothbaum BO, van der Kolk BA, Sikes CR, Farfel GM: Multi-center, double-blind comparison of sertraline and placebo in the treatment of posttraumatic stress disorder. Arch Gen Psychiatry 2001; 58:485-492 · DOI · Paper page
  22. Keller MB, Boland RJ: Implications of failing to achieve successful long-term maintenance treatment of recurrent unipolar major depression. Biol Psychiatry 1998; 44:348-360 · DOI · Paper page
  23. Skoog G, Skoog I: A 40-year follow-up of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1999; 56:121-127 · DOI · Paper page
  24. Greist JH, Jefferson JW: Pharmacotherapy for obsessive-compulsive disorder. Br J Psychiatry Suppl 1988; 35:64-70 · DOI
  25. Londborg PD, Hegel MT, Goldstein S, Goldstein D, Himmelhoch JM, Maddock R, Patterson W, Rausch J, Farfel GM: Sertraline treatment of posttraumatic stress disorder: results of a 24-week open-label extension study. J Clin Psychiatry 2001; 62:325-331 · DOI
  26. Blake DD, Weathers FW, Nagy LM, Kaloupek DG, Klauminzer G, Charney DS, Keane TM: A clinician rating scale for assessing current and lifetime PTSD: the CAPS-1. Behav Ther 1990; 13:187-188
  27. Weathers FW, Litz BT: Psychometric properties of the Clinician-Administered PTSD Scale, CAPS-1. PTSD Res Q 1994; 5:2-6 · DOI
  28. Horowitz MJ, Wilner N, Alvarez W: Impact of Event Scale: a measure of subjective stress. Psychosom Med 1979; 41:209-218 · DOI · Paper page
  29. Zilberg N, Weiss DS, Horowitz MJ: Impact of Event Scale: a cross validation study and some empirical evidence. J Consult Clin Psychol 1982; 50:407-414 · DOI · Paper page
  30. Davidson JR, Book SW, Colket JT, Tupler LA, Roth S, David D, Hertzberg M, Mellman T, Beckham JC, Smith RD, Davison RM, Katz R, Feldman ME: Assessment of a new self-rating scale for post-traumatic stress disorder. Psychol Med 1997; 27:153-160 · DOI · Paper page
  31. Zlotnick C, Davidson J, Shea MT, Pearlstein T: Validation of the Davidson Trauma Scale in a sample of survivors of childhood sexual abuse. J Nerv Ment Dis 1996; 184:255-257 · DOI
  32. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62 · DOI · Paper page
  33. Endicott J, Nee J, Harrison W, Blumenthal R: Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull 1993; 29:321-326 · DOI · Paper page
  34. Viguera AC, Baldessarini RJ, Friedberg J: Discontinuing antidepressant treatment in major depression. Harv Rev Psychiatry 1998; 5:293-306 · DOI · Paper page
  35. Fava M, Judge R, Hoog SL, Nilsson ME, Koke SC: Fluoxetine versus sertraline and paroxetine in major depressive disorder: changes in weight with long-term treatment. J Clin Psychiatry 2000; 61:863-867 · DOI · Paper page

Cited by

See all 228

Metadata

Authors
Davidson, J., Pearlstein, T., Londborg, P., Brady, K. T., Rothbaum, B., Bell, J., Maddock, R., Hegel, M. T., & Farfel, G.
Venue
American Journal of Psychiatry
Published
2001-12-01
Volume
158
Issue
12
Pages
1974-1981
ISSN
  • 0002-953X (ISSN-L)
  • 1535-7228
OpenAlex
W2118542639
Cited by
228
References
4
FWCI
21.36
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy of Sertraline in Preventing Relapse of Posttraumatic Stress Disorder: Results of a 28-Week Double-Blind, Placebo-Controlled Study. https://app.cochat.ai/papers/10.1176/appi.ajp.158.12.1974
The paper
Davidson, J., Pearlstein, T., Londborg, P., Brady, K. T., Rothbaum, B., Bell, J., Maddock, R., Hegel, M. T., & Farfel, G. (2001). Efficacy of Sertraline in Preventing Relapse of Posttraumatic Stress Disorder: Results of a 28-Week Double-Blind, Placebo-Controlled Study. American Journal of Psychiatry. https://doi.org/10.1176/appi.ajp.158.12.1974

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.